Feasibility Defines a Unique Enrollment Strategy
Feasibility Defines a Unique Enrollment Strategy
2 PagesCASE STUDY Feasibility Defines a Unique Enrollment StrategyPRA Health Sciences conducts comprehensive Phase I-IV biopharmaceutical drug development. To learn more about our solutions, please visit us at prahs.com or email us at prahealthsciences@prahs.com. © PRAHS 2019. All rights reserved. JUN2017 Feasibility Defines a Unique Enrollment Strategy PRA performed a feasibility study to identify investigators who treat patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial. It was estimated that there may only be 1,000 to 3,000 patients in the US and Europe with the condition. The major challenge that PRA faced was identifying the investigators and sites that see these patients. The protocol required 42 patients, and it wa
